Online inquiry

IVTScrip™ mRNA-Human ABLIM2, (Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WK12379MR)

This product GTTS-WK12379MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the ABLIM2 protein. This product can be used in Oogenesis phase fetal germ cell-related researches.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Human
RefSeq NM_001130083.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification Chromatography
Target Gene
Gene ID 84448
UniProt ID Q6H8Q1
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Human ABLIM2, (Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WK12379MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WK18446MR IVTScrip™ mRNA-Human AMBN, (Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA AMBN
GTTS-WK27464MR IVTScrip™ mRNA-Human ARNTL2, (Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ARNTL2
GTTS-WK25505MR IVTScrip™ mRNA-Human Apelin, (Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA Apelin
GTTS-WK22343MR IVTScrip™ mRNA-Human ARL4D, (Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ARL4D
GTTS-WK8687MR IVTScrip™ mRNA-Human AFTPH, (Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA AFTPH
GTTS-WK14099MR IVTScrip™ mRNA-Human AGGF1, (Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA AGGF1
GTTS-WK27700MR IVTScrip™ mRNA-Human ARHGAP45, (Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ARHGAP45
GTTS-WK23226MR IVTScrip™ mRNA-Human ARID4B, (Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ARID4B
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW